Drugs / BAT4706
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06139536 | Mar 2024 → Dec 2025 | neoplasm | Bio-Thera Solutions | Unknown | No outcome recorded |
| Phase 1 | NCT05148325 | Sep 2021 → Nov 2024 | melanoma | Bio-Thera Solutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT 4706 | “BAT 4706” NCT05148325 ↗ |
| Modality | Monoclonal antibody | “Fc-glycosylated recombinant fully humanized anti-CTLA-4 monoclonal antibody injection” NCT06139536 ↗ |
| Route | Intravenous | “Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.” NCT06139536 ↗ |